IFPMA commends the Resolution and the recognition of climate change as an urgent global challenge.

Innovative pharmaceutical companies are setting ambitious, science-aligned targets and investing to develop environmentally sustainable products, manufacturing processes, and supply chains, without compromising safety, quality, and efficacy for best patient outcomes.

Pharmaceutical operations are complex and highly regulated, thus collaboration between industry, governments, regulators, and health systems actors, including suppliers, is required. Likewise, the climate change and health nexus is a multi-faceted area demanding solid collaboration.

The ATACH initiative is an important platform for mobilizing the resources and expertise needed to address this crisis. As a formal member of ATACH, IFPMA looks forward to constructively engaging with its actors by leveraging its sector’s experience, such as science and partnerships.